Recent advances in molecularly targeted therapy in advanced renal cell carcinoma

Therapy

Volumn 6, Issue 3, 2009, Pages 309-320

  Kim, Jenny J ^a   Rini, Brian I ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Mammalian target of rapamycin; Monoclonal antibody; Renal cell carcinoma; Targeted therapy; Tyrosine kinase inhibitor; VEGF receptor; von Hippel Lindau

Indexed keywords

ALPHA INTERFERON; AMG 386; AMG 836; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CEDIRANIB; ERLOTINIB; EVEROLIMUS; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PERIFOSINE; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VOLOCIXIMAB; VON HIPPEL LINDAU PROTEIN; XL 880;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE FAILURE; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INDUCED HYPOTHERMIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; LOW DRUG DOSE; MEGALOCYTOSIS; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN TARGETING; PROTEINURIA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS;

EID: 69449090797     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.16     Document Type: Review

References (79)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34(3), 193-205 (2008).
2. Nguyen MM, Gill IS, Ellison LM: The evolving presentation of renal cell carcinoma in the United States: trends from the surveillance, epidemiology and end results program. J. Urol. 176(6), 2397-2400 (2006).
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr: Rising incidence of renal cell cancer in the United States. JAMA 281(17), 1628-1631 (1999).
4. Herman JG, Latif F, Weng Y et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91(21), 9700-9704 (1994).
5. Gallou C, Joly D, Mejean A et al.: Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13(6), 464-475 (1999).
6. Schraml P, Struckmann K, Hatz F et al.: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196(2), 186-193 (2002).
7. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23(5), 1028-1043 (2005)
8. Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13 (Suppl. 2) 680S-684S (2007)
9. Clarkson PE, Cookson MS: The von Hippel-Lindau gene: turning discovery into therapy. Cancer 113 (7 Suppl.), 1768-1778 (2008).
10. Kibel A, Iliopoulos O, DeCaprio JA et al.: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269(5229), 1444-1446 (1995).
11. Maxwell PH, Wiesener MS, Chang GW et al.: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999).
12. Cockman ME, Mason N, Mole DR et al.: Hypoxia inducible factor-a binding and ubiquitylation by the von hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275(33), 25733-25741 (2000).
13. Semenza GL: HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg. Biomembr. 39(3), 231-234 (2007).
14. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 1995 92(12), 5510-5514 (1995).
15. Kondo K, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor gene. Exp. Cell. Res. 264(1), 117-125 (2001).
16. Schueneman AJ, Himmelfarb E, Geng L et al.: SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63(14), 4009-4016 (2003).
17. Mendel DB, Laird AD, Xin X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327-337 (2003).
18. Manning WC, Bello CL, Deprimo SE et al.: Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Program and Abstracts of the American Society of Clinical Oncology 39th Annual Meeting. Chicago, IL, USA, 31 May-3 June (2003) (Abstract 768).
19. Raymond E, Faivre S, Vera C et al.: Final results of a Phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Program and Abstracts of the American Society of Clinical Oncology 39th Annual Meeting. Chicago, IL, USA, 31 May-3 June (2003) (Abstract 769)
20. Motzer RJ, Rini BI, Bukowski RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21), 2516-2524 (2006).
21. Motzer RJ, Dror Michaelson M, Redman BG et al.: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).
22. Figlin RA, Hutson TE, Tomczak P et al.: Overall survival with sunitinib versus interferon (IFN)-α as first-line treatment of metastatic renal cell carcinoma (mRCC). Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30May-3 June (2008) (Abstract 5024).
23. Cella D, Li JZ, Cappelleri JC et al.: Quality of life in patients with metastatic renal cell caricnoma treated with sunitinib or interferon a: results from a Phase III randomized trial. J. Clin. Oncol. 26(22), 3763-3769 (2008).
24. Rini BI, Choueiri TK Elson P et al.: Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 113(6), 1309-1314.
25. Lyons JF, Wilhelm S, Hibner B, Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 8(3), 219-225 (2001).
26. Hilger RA, Scheulen ME, Strumberg D: The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25(6), 511-518 (2002).
27. Wilhelm SM, Carter C, Tang L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
28. Chang YS, Henderson A, Xue D et al.: BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma predominantly through inhibition of tumor angiogenesis. Program and Abstracts of American Association for Cancer Reserch 96th Annual Meeting. Anaheim, CA, USA, 16-20 April (2005) (Abstract 5831).
29. Levy J, Pauloski N, Braun D et al.: Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Program and Abstracts of American Association for Cancer Reserch 97th Annual Meeting. Washington, DC, USA, 1-5 April (2006) (Abstract 906).
30. Awada A, Hendlisz A, Gil T et al.: Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on 7 days off in patients with advanced, refractory solid tumors. Br. J. Cancer 92(10), 1855-1861 (2005).
31. Clark JW, Eder JP, Ryan D et al.: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11(15), 5472-5480 (2005).
32. Moore MJ, Hirte HW, Siu L et al.: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol. 16(10), 1688-1694 (2005).
33. Strumberg D, Richly H, Hilger RA et al.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23(5), 965-972 (2005).
34. Ratain MJ, Eisen T, Stadler WM, Flaherty KT et al.: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(16), 2505-2512 (2006).
35. Escudier B, Eisen T, Stadler WM et al.: Sorafenib in advanced clear-cell renal cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
36. Bukowski RM, Eisen T, Szczylik C et al.: Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker ana lysis. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, June 1-5 (2007) (Abstract 5023).
37. Szcylik C, Demkow T, Staehler M et al.: Randomized Phase II trial of first-line treatment with sorafnib versus interferon in patients with advanced renal cell carcinoma: Final results. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, June 1-5 (2007) (Abstract 5025).
38. Amato RJ, Harris P, Dalton M et al.: A Phase II trial of inter-patient dose-escalated sorafenib in patients with metastatic renal cell cancer. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, June 1-5 (2007) (Abstract 5026)
39. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 438(7070), 967-974 (2005).
40. Kim KJ, Li B, Winer J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362(6423), 841-844 (1993).
41. Yang JC, Haworth L, Sherry RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349(5), 427-434 (2003).
42. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007).
43. Rini BI, Halabi SH, Rosenberg JE et al.: Bevacizumab plus Interferon-α versus Interferon-α monotherapy in patients with metastatic renal cell carcinoma: results of CALGB 90206. J. Clin. Oncol. 26(33), 5422-5428 (2008).
44. Schmelzle T, Hall MN: TOR, a central controller of cell growth. Cell 103(2), 253-262 (2000).
45. Thomas GV, Tran C, Mellinghoff IK et al.: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12(1), 122-127 (2006).
46. Hudson CC, Liu M, Chiang GG et al.: Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22(20), 7004-7014 (2002).
47. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation factor 4E. Mol. Cell Biol. 24(1), 200-216 (2004).
48. Neshat MS, Mellinghoff IK, Tran C et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of fRAP/mTOR. Proc. Natl Acad. Sci. USA 98(18), 10314-10319 (2001).
49. Atkins MB, Hidalgo M, Stadler WM et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004)
50. Mekhail TM, Abou-Jawde RM, Boumerhi G et al.: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005).
51. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999).
52. Hudes G, Carducci M, Tomczak P et al.: Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
53. Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R: A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 5107).
54. Motzer RJ, Escudier B, Oudard S et al.: Ef?cacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
55. Rixe O, Bukowski RM, Michaelson MD et al.: Axitinib treatment in patient with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet 8 (11), 975-984 (2007).
56. Rini BI, Wilding GT, Hudes G et al.: Axitinib in patients with metastatic renal cell cancer refractory sorafenib. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 5032).
57. Hutson TE, Davis ID, Machiels JP et al.: Pazopanib (GW786034) is active in metastatic renal cell carcinoma: interim results of a Phase II randomized discontinuation trial. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 5031).
58. Sridhar SS, Hotte SJ, Mackenzie MJ et al.: Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma: a trial of the PMH Phase II Consortium. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 5093).
59. Van Herpen C, Drevs J, van Cruijsen H et al.: Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinioma: combined results from two Phase I studies. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 3560)
60. Sridhar SS, Mackenzie MJ, Hotte SJ et al.: Activity of cediranib (AZD2171) in patients with previously untreated metastatic renal cell cancer. A Phase II trial of the PMH Consortium. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 5047).
61. Yazji S, Bukowski R, Kondagunta V, Figlin R: Final results from Phase II study of volociximab, an α5β1 anti-integrin antibody, in refractory or relapsed metastatic clear cell renal cell carcinoma. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 5094)
62. Rini BI, Michaelson MD, Rosenberg JE et al.: antitumor activity and biomarker ana lysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743-3748 (2008).
63. Rini BI, Hutson TE, Elson P et al.: A prospective trial of sorafenib in patients with metastatic clear cell renal cell carcinoma refractory to prior sunitinib or bevacizumab. ASCO 2008 GU Cancers Symposium. San Francisco, CA, USA, 14-16 February (2008) (Abstract 346).
64. Sosman JA, Puzanov I, Atkins MB: Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 13(2 Suppl.), 764S-769S (2007).
65. Schmidinger M, Vogl UM, Lamm W, Bojic M, Bojic A, Zielinski CC: Temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma: preliminary results from the austrian compassionate use program. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 16125).
66. Feldman DR, Ginsberg M, Baum C et al.: Phase I trial of bwvacizumab plus sunitinib in patients with metastatic renal cell carcinoma. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 5100).
67. Sosman JA, Flaherty KT, Atkins MB, McDermott DF, Rothenberg ML et al.: Updated results of Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell carncer. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 5011).
68. Eto M, Takeuchi A, Ohki T, Tatsugami K, Naito S: In vitro and in vivo analysis of synergistic antitumor effects of interferon-a and sorafenib in renal cell carcinoma. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 16143)
69. Golob JA, Rathmell WK, Richmond TM et al.: Phase II trial of sorafenib plus interferon α-2a as first- or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 25(22), 3288-3295 (2007).
70. Rosenberg JE, Weinberg VK, Claros C et al.: Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 5109).
71. Whorf RC, Hainsworth JD, Spigel DR et al.: Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 5010).
72. Stephenson J, Schreeder M, Waples J et al.: Perifosine, active as a single agent for renal cell carcinoma, now in Phase I trials combined with tyrosine kinase inhibitors. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 15622).
73. Schreeder MT, Figlin RA, Stephenson JJ et al.: Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinioma. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 16024).
74. Bukowski RM, Fairooz F, Kabbinavar RA et al.: Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25(29), 4536-4541 (2007).
75. Choueiri TK, Plantade A, Elson P et al.: Ef?cacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26(1), 127-121 (2008).
76. Dutcher J, de Souza P, Figlin R et al.: Effect of temsirolimus versus interferon-a on survival of patients with advanced renal cell carcinoma of different tumor histologies. ASCO 2008 GU Cancers symposium. San Francisco, CA, USA, 14-16 February (2008) (Abstract 384).
77. Eder J, Heath E, Appleman L et al.: Phase I experience wih c-MET inhibitor XL880 administered orally to patients with solid tumors. Program and Abstracts of the American Society of Clinical Oncology 43rd Annual Meeting. Chicago, IL, USA, 1-5 June (2007) (Abstract 3526).
78. Srinivasan R, Choueiri TK, Vaishampayan U et al.: A Phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients with papillary renal cell carcinoma. Program and Abstracts of the American Society of Clinical Oncology 44th Annual Meeting. Chicago, IL, USA, 30 May-3 June (2008) (Abstract 5103).
79. Oliner J, Min H, Leal J et al.: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6(5), 507-516 (2004).